Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Neoplasm MetastasesRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00556049
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center', Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
- Conditions
- Stomach Neoplasms
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00555672
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
- Conditions
- Stomach Neoplasms
- Interventions
- First Posted Date
- 2007-11-08
- Last Posted Date
- 2013-01-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT00555620
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT00553696
- Locations
- 🇯🇵
Saku Central Hospital, GI Devision, Saku, Nagano, Japan
🇯🇵Aichi cancer center central hospital / Medical Oncology, Nagoya, Aichi, Japan
🇯🇵Shizuoka Cancer Center, Suntougun, Shizuoka, Japan
Bevacizumab in Multiple Phase I Combinations
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 343
- Registration Number
- NCT00543504
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
- Conditions
- Platinum Refractory Epithelial Ovarian CancerPrimary Cancer of the PeritoneumCancer of the Fallopian Tube
- Interventions
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- AGO Study Group
- Target Recruit Count
- 73
- Registration Number
- NCT00543049
- Locations
- 🇩🇪
Malterser-Krankenhaus Bonn-Rhein/Sieg, Frauenklinik, Bonn, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus, Klinik u. Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Germany
🇩🇪Universitätsklinikum, Universitätsfrauenklinik, Ulm, Germany
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
- Conditions
- Kidney Cancer
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 92
- Registration Number
- NCT00541008
- Locations
- 🇫🇷
Hopital Saint Michel, Paris, France
🇫🇷CHU de la Timone, Marseille, France
🇫🇷Centre Paul Papin, Angers, France
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
- Conditions
- Kidney (Renal Cell) CancerKidney NeoplasmsCarcinoma, Renal Cell
- Interventions
- Procedure: FDG PET CTProcedure: DCE MRIDrug: F-18 Fluoro-deoxi-glucoseDrug: Gadolinium-DTPADrug: Sunitinib
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 17
- Registration Number
- NCT00537056
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2010-08-30
- Lead Sponsor
- Medical University Innsbruck
- Target Recruit Count
- 70
- Registration Number
- NCT00535379
- Locations
- 🇦🇹
LKH Feldkirch, Feldkirch, Austria
🇦🇹LNK Wagner-Jauregg, Linz, Austria
🇩🇪University Hospital of Bonn, Bonn, Nordrhein-Westfalen, Germany
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00526656
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.